ADMA Biologics (ADMA) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Mizuho | Maintained | Outperform | $17.00 from $20.00 | Jul 15, 2026 |
| Mizuho | Maintained | Outperform | $20.00 from $24.00 | May 7, 2026 |
| Canaccord Genuity | Maintained | Buy | $18.00 from $21.00 | May 7, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $21.00 | Apr 21, 2026 |
| Mizuho | Maintained | Outperform | $24.00 from $30.00 | Apr 13, 2026 |
| Cantor Fitzgerald | Downgraded | Overweight → Neutral | — | Mar 26, 2026 |
| Raymond James | Maintained | Strong Buy | $32.00 from $25.00 | May 8, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $25.00 | Mar 4, 2025 |
| Raymond James | Maintained | Strong Buy | $25.00 from $18.00 | Nov 8, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $26.00 from $18.00 | Nov 8, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 | Oct 14, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $20.00 | Sep 20, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $10.00 | Aug 12, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $20.00 from $15.00 | Aug 9, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $15.00 from $10.00 | Jul 9, 2024 |
| Mizuho | Maintained | Buy | $14.00 from $12.00 | Jun 20, 2024 |
| Mizuho | Maintained | Buy | $12.00 from $10.00 | May 10, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $7.50 | May 10, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $10.00 from $8.00 | May 10, 2024 |
| Raymond James | Maintained | Strong Buy | $10.00 from $8.00 | May 10, 2024 |
Frequently asked questions
Is ADMA a buy, sell, or hold?
Analysts covering ADMA Biologics currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ADMA?
On Jul 15, 2026, Mizuho maintained ADMA Biologics at Outperform with a price target of $17.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.